- Home
- NMCO vs LXRX Comparison
NMCO vs LXRX Comparison
Compare NMCO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | LXRX |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 591.6M | 703.3M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NMCO | LXRX |
|---|---|---|
| Price | $10.72 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 124.9K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $9.95 | $0.52 |
| 52 Week High | $10.99 | $2.53 |
Technical Indicators
Market Signals| Indicator | NMCO | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 65.84 |
| Support Level | $10.65 | $1.44 |
| Resistance Level | $10.79 | N/A |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 19.23 | 71.78 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.